Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1452

Sort by

Sort Order Select

Journal Articles

Cryptic insertion of KMT2A , a rare t(9;11) variant

Nada Assaf, Christine Terré

Blood (2021) 137 (13): 1843.

https://doi.org/10.1182/blood.2020010442

Published: 2021

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Faster Diagnosis of TTP Using New Technoscreen Adamts-13 Activity Assay

Annica Braf, Henrik von Horn, Niklas Bark, Eva-Marie Norberg, Asa Truedsson, Nikolaus B Binder, MD PhD, Jovan P Antovic, MD PhD

Blood (2019) 134 (Supplement_1): 2354.

https://doi.org/10.1182/blood-2019-128131

Published: 2019

Journal Articles

A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia

Alexandre Bazinet, MD, Ryan N Rys, BSc, BA, Claudia M Wever, PhD, Amadou Barry, Celia Greenwood, PhD, Christian Young, Alma Mendoza, Ida LaPorta, Sylvain Gimmig, François Mercier, MD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 5451.

https://doi.org/10.1182/blood-2019-123904

Published: 2019

Journal Articles

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Prue Hardefeldt, MBBS, John Moore, MDFRACP,FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Keith Fay, FRCP,FRCPath,MB, Lavee Orly, MBBS, Eleni Mayson, FRACP, FRCPA, MBBS, MPhil, Barbara Withers, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2019) 134 (Supplement_1): 5336.

https://doi.org/10.1182/blood-2019-125154

Published: 2019

Journal Articles

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 5491.

https://doi.org/10.1182/blood-2019-131730

Published: 2019

Journal Articles

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

Shi Hui Clarice Choong, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD, Sanjay De Mel, BSc, BM, Te-Chih Liu, FRCPath, MBBS, MRCP, Bei Jenny Li, Li Mei Michelle Poon, Shir Ying Lee, FRCPath,MBBS,MRCP,, Hoon Chung Tae, Rebecca Teng, Seok Wei Stephrene Chan

Blood (2019) 134 (Supplement_1): 5253.

https://doi.org/10.1182/blood-2019-125241

Published: 2019

Journal Articles

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Kristen M Corrao, MD, Alexandra M. Harrington, MDMT(ASCP), Steven H. Kroft, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5430.

https://doi.org/10.1182/blood-2019-130511

Published: 2019

Journal Articles

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Irene Scarfò, PhD, Kathleen Gallagher, Marcela V. Maus, MD PhD, Rebecca Larson, BS, Maegan Sheehan, BS, Gabrielle Brini, MSc, Scott Bornheimer, Mary Beth Hanley, Matthew Frigault, MD MSc, Mark Leick, MD, Alena Chekmasova, PhD

Blood (2019) 134 (Supplement_1): 5626.

https://doi.org/10.1182/blood-2019-128745

Published: 2019

Journal Articles

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

Rebecka Svanberg, MD, Sisse Rye Ostrowski, MD PhD DMSc, Ass Prof, Jakob Thaning Bay, MD PhD, Lars Peter Ryder, MSc, PhD, Hanne Vibeke Vibeke Marquart, Arnon P Kater, MD PhD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4289.

https://doi.org/10.1182/blood-2019-123410

Published: 2019

Journal Articles

High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)

Alexander R. Vartanov, MD, Stacey M. Fernandes, BS, Winnie I Nguy, Danielle M. Brander, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Allison P. Jacob, Jon E. Arnason, MD, Jeremy S. Abramson, MD MMSc, Matthew S. Davids, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 4291.

https://doi.org/10.1182/blood-2019-124305

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Myeloid Neoplasms with t(12;22)(p13;q12) and MN1 Ectopia Are Refractory to Chemotherapy and Can Benefit from Hematopoietic Stem Cell Transplantation

Tong Wang, Xue Chen, MD, Shuang Hui, Jingbo Ni, Ying Yin, Wei Cao, Yan Zhang, Xinyu Wang, Xiaoli Ma, Panxiang Cao, Mingyue Liu, Kylan N. Chen, Fang Wang, MD, Yang Zhang, MD, Daijing Nie, MD, Lili Yuan, Hongxing Liu

Blood (2019) 134 (Supplement_1): 2721.

https://doi.org/10.1182/blood-2019-131610

Published: 2019

Journal Articles

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Blood (2019) 134 (Supplement_1): 2755.

https://doi.org/10.1182/blood-2019-122311

Published: 2019

Journal Articles

Investigation of Homing Capacity As Prognostic Marker in Human Acute Myeloid Leukemia

Pauline Hanns, MSc, Marcelle Baer, MSc, Anna M Paczulla, PhD, Martina Konantz, PhD, Claudia Lengerke, MD

Blood (2019) 134 (Supplement_1): 2701.

https://doi.org/10.1182/blood-2019-127647

Published: 2019

Journal Articles

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Colin D. Godwin, MDMPhil, Yi Zhou, MD PhD, Megan Othus, PhD, Carole M. Shaw, BA, Kelda M. Gardner, PA-C, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2729.

https://doi.org/10.1182/blood-2019-127128

Published: 2019

Journal Articles

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Prashant Tembhare, MD, Gaurav Narula, MD, Gaurav Chatterjee, MD, Twinkle Khanka, Mahima Sanyal, Sitaram Ghogale, Nikhil Patkar, MD, Nilesh Deshpande, Yajamanam Badrinath, Sumeet Gujral, MD, Shripad Banavali, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2585.

https://doi.org/10.1182/blood-2019-128347

Published: 2019

Journal Articles

Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia

Ilaria Tanasi, Veronica Tagliaferri, Cristina Tecchio, Fiorenza Aprili, Giovanna De Matteis, Giovanni Pizzolo, Mauro Krampera, Massimiliano Bonifacio, MD

Blood (2019) 134 (Supplement_1): 2587.

https://doi.org/10.1182/blood-2019-130160

Published: 2019

Journal Articles

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Tomasz Zal, PhD, Mateusz Rytelewski, PhD, Rodrigo Jacamo, PhD, Malgorzata Anna Zal, MSc, Meenakshi Shanmugasundaram, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2674.

https://doi.org/10.1182/blood-2019-131945

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cryptic insertion of KMT2A , a rare t(9;11) variant

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Faster Diagnosis of TTP Using New Technoscreen Adamts-13 Activity Assay

A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Myeloid Neoplasms with t(12;22)(p13;q12) and MN1 Ectopia Are Refractory to Chemotherapy and Can Benefit from Hematopoietic Stem Cell Transplantation

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Investigation of Homing Capacity As Prognostic Marker in Human Acute Myeloid Leukemia

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only